You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

~ Buy the EXEM FOAM KIT (air polymer-type a) Drug Profile, 2024 PDF Report in the Report Store ~

EXEM FOAM KIT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Exem Foam Kit, and what generic alternatives are available?

Exem Foam Kit is a drug marketed by Giskit and is included in one NDA. There are three patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in EXEM FOAM KIT is air polymer-type a. There are thirty-seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the air polymer-type a profile page.

DrugPatentWatch® Generic Entry Outlook for Exem Foam Kit

Exem Foam Kit was eligible for patent challenges on November 7, 2023.

Indicators of Generic Entry

< Available with Subscription >

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for EXEM FOAM KIT?
  • What are the global sales for EXEM FOAM KIT?
  • What is Average Wholesale Price for EXEM FOAM KIT?
Summary for EXEM FOAM KIT
International Patents:6
US Patents:3
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
DailyMed Link:EXEM FOAM KIT at DailyMed
Drug patent expirations by year for EXEM FOAM KIT

US Patents and Regulatory Information for EXEM FOAM KIT

EXEM FOAM KIT is protected by three US patents and one FDA Regulatory Exclusivity.

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Exclusivity Expiration
Giskit EXEM FOAM KIT air polymer-type a FOAM;INTRAUTERINE 212279-001 Nov 7, 2019 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Giskit EXEM FOAM KIT air polymer-type a FOAM;INTRAUTERINE 212279-001 Nov 7, 2019 RX Yes Yes ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Giskit EXEM FOAM KIT air polymer-type a FOAM;INTRAUTERINE 212279-001 Nov 7, 2019 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
Giskit EXEM FOAM KIT air polymer-type a FOAM;INTRAUTERINE 212279-001 Nov 7, 2019 RX Yes Yes ⤷  Subscribe ⤷  Subscribe Y ⤷  Subscribe
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Exclusivity Expiration
Showing 1 to 4 of 4 entries

International Patents for EXEM FOAM KIT

See the table below for patents covering EXEM FOAM KIT around the world.

CountryPatent NumberTitleEstimated Expiration
Denmark 2488211 ⤷  Subscribe
European Patent Office 2488211 Composition et procédé d'imagerie médicale de cavités corporelles (Composition and method for medical imaging of body cavities) ⤷  Subscribe
Netherlands 2003660 ⤷  Subscribe
Poland 2488211 ⤷  Subscribe
Spain 2529564 ⤷  Subscribe
World Intellectual Property Organization (WIPO) 2011046437 ⤷  Subscribe
>Country>Patent Number>Title>Estimated Expiration
Showing 1 to 6 of 6 entries

Market Dynamics and Financial Trajectory for the ExEm Foam Kit

Introduction to ExEm Foam Kit

The ExEm Foam Kit, developed by Dutch gynecologists Dr. Niek Exalto and Prof. Dr. Mark Hans Emanuel, is a revolutionary tool in the field of infertility diagnosis. It is used for hysterosalpingo foam sonography (HyFoSy), a procedure that assesses the patency of the fallopian tubes using ultrasound technology. This innovation has significantly impacted the market for tubal patency testing, offering a less invasive and more patient-friendly alternative to traditional methods like X-ray hysterosalpingography (HSG) and laparoscopy.

Market Need and Demand

The demand for assisted reproductive technologies has been on the rise, driven by increasing rates of infertility and a growing preference for less invasive diagnostic procedures. With the introduction of ExEm Foam, there has been a notable shift towards ultrasound-based tubal patency testing. This is partly due to the downward trend in using radiation in women trying to conceive, as highlighted by Johan Remmerswaal, President of ExEm Foam Inc.[4].

Competitive Landscape

ExEm Foam is the only FDA-approved contrast agent for ultrasound tubal patency testing, giving it a unique position in the market. Traditional methods such as X-ray HSG and laparoscopy, while effective, come with significant drawbacks including the use of radiation and iodine, and the need for additional appointments. ExEm Foam's non-invasive nature and lack of radiation make it a preferred choice for many healthcare providers and patients[4].

Global Adoption and Usage

Since its launch in Europe in 2011, ExEm Foam has been used in over 1 million fallopian tubes worldwide, with more than 500,000 procedures conducted globally. Its availability has expanded to select fertility clinics in the United States following FDA approval in 2019. This widespread adoption underscores the product's efficacy and acceptance within the medical community[1][4].

Clinical Effectiveness

Multiple studies, including the 'FOAM Study' presented at the 2019 American Society of Reproductive Medicine (ASRM) Scientific Congress, have demonstrated that ExEm Foam has similar effectiveness to X-ray HSG. The study, which involved 1167 patients in 26 hospitals, found that 12-month pregnancy outcomes were similar for subfertile women who received HyFoSy with ExEm Foam compared to those who underwent X-ray HSG[3].

Cost and Insurance Coverage

The financial trajectory of ExEm Foam is influenced by its cost and insurance coverage. Depending on the insurance plan, ExEm Foam could be fully covered, resulting in no copay, deductible, or out-of-pocket costs for patients. Patients are advised to verify coverage with their insurance providers, using the J code: J3490. If not covered under medical benefits, it may be covered as a pharmacy benefit. For those without insurance or insufficient coverage, self-pay options are available through the pharmacy[2].

Revenue and Growth

The revenue generated by ExEm Foam is substantial, given its widespread use and the growing demand for assisted reproductive technologies. The product's availability in multiple regions, including Europe and the United States, contributes to its financial success. While exact revenue figures are not publicly disclosed, the fact that it has been used in over 500,000 procedures worldwide since its launch indicates a significant revenue stream.

Market Expansion and Future Prospects

ExEm Foam Inc is headquartered in Nashville, TN, and continues to expand its reach to more fertility clinics. The company's focus on providing innovative solutions to simplify infertility diagnosis and enhance the fertility journey positions it for continued growth. As more healthcare providers adopt the HyFoSy procedure, the demand for ExEm Foam is expected to increase, driving further market expansion and revenue growth[4].

Patient and Healthcare Provider Acceptance

The acceptance of ExEm Foam among patients and healthcare providers is high due to its less invasive nature and the absence of radiation. Patients appreciate the comfort and convenience of the procedure, which can be performed in the gynecologist's office. Healthcare providers value the accuracy and ease of use of the ExEm Foam Kit, making it a preferred diagnostic tool for tubal patency testing[4].

Regulatory Environment

ExEm Foam's FDA approval in 2019 was a significant milestone, validating its safety and efficacy. This regulatory approval has facilitated its adoption in the U.S. market and reinforced its position as a trusted diagnostic tool. Compliance with regulatory standards ensures that the product meets high safety and efficacy criteria, further enhancing its market credibility[4].

Safety and Efficacy

ExEm Foam has been proven to be safe and effective in numerous clinical trials. The product is indicated for use as a contrast agent for HyFoSy to assess fallopian tube patency in women with known or suspected infertility. The safety profile of ExEm Foam is robust, with no significant adverse effects reported in extensive clinical use[4].

Conclusion

The ExEm Foam Kit has revolutionized the field of infertility diagnosis by offering a less invasive, radiation-free alternative for tubal patency testing. Its widespread adoption, strong clinical evidence, and favorable insurance coverage have contributed to its financial success. As the demand for assisted reproductive technologies continues to grow, ExEm Foam is well-positioned for continued market expansion and revenue growth.

Key Takeaways

  • Innovative Diagnostic Tool: ExEm Foam is the only FDA-approved contrast agent for ultrasound tubal patency testing.
  • Global Adoption: Used in over 1 million fallopian tubes worldwide since its launch in 2011.
  • Clinical Effectiveness: Proven to have similar effectiveness to X-ray HSG in multiple studies.
  • Cost and Insurance: May be fully covered by insurance, with self-pay options available.
  • Market Expansion: Continues to expand to more fertility clinics globally.
  • Patient and Provider Acceptance: High acceptance due to its less invasive nature and absence of radiation.

FAQs

Q: What is the ExEm Foam Kit used for? A: The ExEm Foam Kit is used for hysterosalpingo foam sonography (HyFoSy) to assess the patency of the fallopian tubes in women with known or suspected infertility.

Q: Is ExEm Foam FDA-approved? A: Yes, ExEm Foam is FDA-approved as a contrast agent for ultrasound tubal patency testing.

Q: How does ExEm Foam compare to traditional methods like X-ray HSG? A: ExEm Foam is less invasive and does not use radiation, making it a preferred choice over traditional methods like X-ray HSG.

Q: Is ExEm Foam covered by insurance? A: Yes, ExEm Foam may be fully covered by insurance, depending on the specific plan. Patients should verify coverage with their insurance providers.

Q: Where is ExEm Foam available? A: ExEm Foam is available at select fertility clinics in Europe and the United States.

Sources

  1. The Science - ExEm Foam. Exemfoam.eu.
  2. Cost and Insurance Coverage - ExEm Foam. Exemfoam.com.
  3. The Science - ExEm Foam. Exemfoam.com.
  4. ExEm® Foam, the only FDA-approved contrast agent for ultrasound tubal patency testing, is now available at select fertility clinics nationwide. Exemfoam.com.
  5. ExEm Foam Kit - Idoman Teoranta. Idoman-med.com.

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.